Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.

Published

Journal Article

BACKGROUND: Current treatment for medulloblastoma, which includes postoperative radiotherapy and 1 year of chemotherapy, does not cure many children with high-risk disease. We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma. METHODS: After resection, patients were classified as having average-risk medulloblastoma (< or = 1.5 cm2 residual tumour and no metastatic disease) or high-risk medulloblastoma (> 1.5 cm2 residual disease or metastatic disease localised to neuraxis) medulloblastoma. All patients received risk-adapted craniospinal radiotherapy (23.4 Gy for average-risk disease and 36.0-39.6 Gy for high-risk disease) followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy. Patients were assessed regularly for disease status and treatment side-effects. The primary endpoint was 5-year event-free survival; we also measured overall survival. This study is registered with ClinicalTrials.gov, number NCT00003211. FINDINGS: Of 134 children with medulloblastoma who underwent treatment (86 average-risk, 48 high-risk), 119 (89%) completed the planned protocol. No treatment-related deaths occurred. 5-year overall survival was 85% (95% CI 75-94) in patients in the average-risk group and 70% (54-84) in those in the high-risk group (p=0.04); 5-year event-free survival was 83% (73-93) and 70% (55-85), respectively (p=0.046). For the 116 patients whose histology was reviewed centrally, histological subtype correlated with 5-year event-free survival (p=0.04): 84% (74-95) for classic histology, 77% (49-100) for desmoplastic tumours, and 57% (33-80) for large-cell anaplastic tumours. INTERPRETATION: Risk-adapted radiotherapy followed by a shortened schedule of dose-intensive chemotherapy can be used to improve the outcome of patients with high-risk medulloblastoma.

Full Text

Duke Authors

Cited Authors

  • Gajjar, A; Chintagumpala, M; Ashley, D; Kellie, S; Kun, LE; Merchant, TE; Woo, S; Wheeler, G; Ahern, V; Krasin, MJ; Fouladi, M; Broniscer, A; Krance, R; Hale, GA; Stewart, CF; Dauser, R; Sanford, RA; Fuller, C; Lau, C; Boyett, JM; Wallace, D; Gilbertson, RJ

Published Date

  • October 2006

Published In

Volume / Issue

  • 7 / 10

Start / End Page

  • 813 - 820

PubMed ID

  • 17012043

Pubmed Central ID

  • 17012043

International Standard Serial Number (ISSN)

  • 1470-2045

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(06)70867-1

Language

  • eng

Conference Location

  • England